New drug combo shows promise for tough bile duct cancer
NCT ID NCT06938321
First seen Mar 09, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study is for people with advanced biliary tract cancer (a type of bile duct cancer) that has not responded to other treatments. It tests a combination of two drugs, AK130 and AK112, to see if they are safe and can shrink tumors. The study has two parts: first, finding the best dose, and then, checking how well the treatment works in about 135 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.